Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06335173
Status:
RECRUITING
Last Update Posted:
2024-07-10
First Post:
2024-03-13
Brief Title:
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimers Disease ALTITUDE-AD
Sponsor:
Acumen Pharmaceuticals
Organization:
Acumen Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheimers Disease
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ALTITUDE-AD
Brief Summary:
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks Q4W in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimers disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-509807-34-00 | REGISTRY | EU CT Number | None |